Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy

Table 1 Demographic and clinical characteristics of the patients n (%)

Characteristics	Value
Total	120 (100)
Age, yr
mean ± SD	49.6 ± 10.5
Median (range)	18-72
Gender
Male	71 (59.2)
Female	49 (40.8)
KPS
≥ 80%	96 (80.0)
70%	20 (16.7)
60%	4 (3.3)
Primary tumor
Right-sided	33 (27.5)
Left-sided	87 (72.5)
Histology
Glandular	89 (74.2)
Mucinous	13 (10.8)
Signet-ring cell	3 (2.5)
Mixed	10 (8.3)
Unfixed	5 (4.2)
First-line chemotherapy
FOLFIRI	109 (90.8)
mXELIRI	7 (5.8)
Irinotecan	4 (3.3)
Serum total bilirubin, μmol/L
mean ± SD	10.2 ± 4.3
Range	3.1-26.9
Serum unconjugated bilirubin, μmol/L
mean ± SD	7.2 ± 3.1
Range	2.5-19.2
UGT1A1*28 genotype1
(TA)6/6	84 (70.0)
(TA)6/7	34 (28.3)
(TA)7/7	2 (1.7)

¹Variants were in Hardy-Weinberg equilibrium (P > 0.05). KPS: Karnofsky performance status.